Biologic therapy in supra-aortic Takayasu arteritis can improve symptoms of cerebral ischaemia without surgical intervention
- 1 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (Supplement), 28-32
- https://doi.org/10.1093/rheumatology/kez616
Abstract
Objectives. Takayasu arteritis commonly results in severe arterial injury with stenoses, occlusions and occasionally aneurysms. Arterial disease may compromise organ blood flow and result in significant cardiovascular morbidity and premature mortality. Involvement of the supra-aortic arteries is common, and in its most severe form may compromise cerebral blood supply, resulting in signs of cerebral ischaemia including visual impairment, dysphasia, transient hemiparesis, loss of consciousness and stroke. In addition to combination immunosuppression, the management paradigm for symptomatic cerebral ischaemia includes revascularization. The invasive nature of this surgery, the risk of complications and the relatively high rate of re-stenosis is of concern to patients and their physicians alike. The aim of this study was to determine whether combined immunosuppression with early escalation to biologic therapy improved outcomes and reduced the need for high risk surgical intervention. Methods. A retrospective review of 145 Takayasu arteritis patients attending Imperial College Healthcare between 2010-2018 was conducted to identify those with cerebral ischaemia secondary to supra-aortic disease and to analyse their treatment and outcomes. Results. Eight patients (5.5%) were identified. Seven patients received long-term combined immunosuppressive therapy and six were prescribed biologics. The data revealed a higher than expected comprehensive response to therapy, with significant falls in disease activity, the cerebral ischaemia score and the prednisolone dose required, over a median follow-up of 37 months. Serial imaging analysis detected no arterial disease progression after the initiation of optimal therapy. Only one patient required surgical intervention for persistent neurological symptoms. Conclusion. Early use of biologic therapy in those with supra-aortic Takayasu arteritis presenting with cerebral ischaemia may reduce the numbers of patients requiring surgical intervention and improve outcomes.Funding Information
- infrastructure support
- Imperial College, National Institute for Health Research Biomedical Research Centre
- University of Cambridge
This publication has 18 references indexed in Scilit:
- Takayasu arteritis: advanced understanding is leading to new horizonsRheumatology, 2018
- Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)Annals Of The Rheumatic Diseases, 2017
- Efficacy of Biological-Targeted Treatments in Takayasu ArteritisCirculation, 2015
- Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral CenterThe Journal of Rheumatology, 2013
- Takayasu arteritis—advances in diagnosis and managementNature Reviews Rheumatology, 2010
- Mycophenolate mofetil in Takayasu’s arteritisClinical Rheumatology, 2010
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals Of The Rheumatic Diseases, 2008
- Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patientsArthritis & Rheumatism, 2007
- Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexateArthritis & Rheumatism, 1994
- Takayasu's Arteritis and Its TherapyAnnals of Internal Medicine, 1985